Literature DB >> 27371164

Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris.

Neveen Salah Seifeldin1, Shereen Bendary El Sayed2, Marwa Kamal Asaad3.   

Abstract

BACKGROUND: Increasing evidence has shown that serum microRNA (miR) levels are useful biomarkers for the diagnosis, prognosis, and therapeutic value in various diseases. Psoriasis is characterized by a specific miR expression profile, with a characteristic miR signature, distinct from that of healthy skin.
OBJECTIVES: To understand the role of miR-1266 in the pathogenesis of psoriasis and to explore if it has the potential as a blood biomarker. We assessed serum miR-1266 levels in patients with psoriasis before and after treatment and compared it with controls. In addition, we evaluated the relationship between miR-1266 and clinical severity in psoriasis before and after treatment.
METHODS: miR-1266 was measured using real-time polymerase chain reaction in 35 patients with chronic plaque psoriasis and 35 healthy controls before and after treatment. Moreover, the correlation between miR-1266 levels and psoriasis area and severity index score was determined.
RESULTS: Serum miR-1266 levels were considerably higher in patients with psoriasis than in healthy control subjects. Furthermore, miR-1266 levels showed a strong positive correlation with psoriasis area and severity index score before and after treatment, having a marked decline with therapy.
CONCLUSION: miR-1266 may have an important role in the pathogenesis of psoriasis vulgaris. This may presumably have possible future implications on the treatment of this chronic disease.
© 2016 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27371164     DOI: 10.1111/ijd.13102

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

Review 1.  MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis.

Authors:  Sandra Domingo; Cristina Solé; Teresa Moliné; Berta Ferrer; Josefina Cortés-Hernández
Journal:  Cells       Date:  2020-12-10       Impact factor: 6.600

2.  Is microRNA 1910-3p (miR-1910-3p) a really distinctive marker for psoriasis?

Authors:  Melek Karabacak; İjlal Erturan; Kuyaş Hekimler Öztürk; Havva Hilal Ayvaz; Selma Korkmaz; Mehmet Yıldırım; Hikmet Orhan
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

3.  Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris.

Authors:  Yi-Zhi Zheng; Chun-Feng Chen; Li-Ying Jia; Tu-Gen Yu; Jie Sun; Xiao-Yong Wang
Journal:  Oncotarget       Date:  2017-04-20

4.  Influence of Adalimumab on the Expression Profile of Genes Associated with the Histaminergic System in the Skin Fibroblasts In Vitro.

Authors:  Dominika Wcisło-Dziadecka; Beniamin Grabarek; Nikola Zmarzły; Aleksandra Skubis; Bartosz Sikora; Celina Kruszniewska-Rajs; Joanna Gola; Urszula Mazurek; Eugeniusz Kucharz
Journal:  Biomed Res Int       Date:  2018-01-02       Impact factor: 3.411

5.  Plasma MicroRNA Expression Profiles in Psoriasis.

Authors:  Shiju Xiao; Xin Liu; Xiaoxu Wang; Hongpeng Lv; Junbo Zhao; Xinwei Guo; Fuyang Xian; Yunrun Ji; Guangzhong Zhang
Journal:  J Immunol Res       Date:  2020-01-16       Impact factor: 4.818

6.  Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients.

Authors:  Cristina Aguilar-Flores; Octavio Castro-Escamilla; Elizabeth M Ortega-Rocha; César Maldonado-García; Fermín Jurado-Santa Cruz; Gibrán Pérez-Montesinos; Alicia Lemini-López; Laura C Bonifaz
Journal:  Mediators Inflamm       Date:  2020-07-31       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.